Literature DB >> 22567172

Morphine-induced conditioned place preference and associated behavioural plasticity in HIV-1 transgenic rats.

Natasha F Homji, Michael Vigorito, Sulie L Chang.   

Abstract

The prevalence of morphine addiction in HIV-1 infected persons is higher than the healthy population. The mu-opioid receptor (MOR) which mediates the actions of morphine is shown to be up-regulated in the HIV-1 transgenic (HIV-1Tg) rat. In this study, we used the conditioned place preference (CPP) test to investigate if HIV-1Tg rats are more sensitive to the addictive properties of morphine compared to F344 control animals. Morphine-CPP was successfully established in the HIV-1Tg and F344 rats at the dose of 3.5 mg/kg. Interestingly, the animals that had morphine paired with one side of the two-chamber CPP apparatus (the white chamber) failed to show any decline in preference for the morphine-paired chamber after 17 to 20 days of extinction testing. An analysis of the change in preference that occurs within a session as a result of the habituation of exploratory behaviour suggested that morphine enhanced a natural preference for the white chamber. We suggest that the morphine CPP procedure may sometimes result in a behavioural plasticity that does not conform to the predictive learning model of classical conditioning and may reflect a form of associative learning known as evaluative conditioning. The animals that had morphine paired with the other chamber (the black chamber) showed extinction. Moreover greater resistance to extinction was observed in the HIV-1Tg rats. Following extinction the HIV-1Tg and F344 groups were each divided into two groups. One group was tested for reinstatement following a 1 mg/kg and 3.5 mg/kg morphine prime on 2 consecutive days, respectively. The second group was tested for reinstatement after exposure to foot shock. Reinstatement with drug-prime or with the foot shock stressor was not observed.

Entities:  

Keywords:  HIV-1Tg rat; Morphine; behavioural plasticity; conditioned place preference (CPP) test; mu-opioid receptor

Year:  2012        PMID: 22567172      PMCID: PMC3342709     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  53 in total

1.  HIV risk behaviour correlates among injecting drug users in Greek prisons.

Authors:  G Koulierakis; C Gnardellis; D Agrafiotis; K G Power
Journal:  Addiction       Date:  2000-08       Impact factor: 6.526

2.  Preexposure to foot-shock sensitizes the locomotor response to subsequent systemic morphine and intra-nucleus accumbens amphetamine.

Authors:  M Leyton; J Stewart
Journal:  Pharmacol Biochem Behav       Date:  1990-10       Impact factor: 3.533

3.  Extinction of drug- and withdrawal-paired cues in animal models: relevance to the treatment of addiction.

Authors:  Karyn M Myers; William A Carlezon
Journal:  Neurosci Biobehav Rev       Date:  2010-01-28       Impact factor: 8.989

Review 4.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues.

Authors:  T M Tzschentke
Journal:  Prog Neurobiol       Date:  1998-12       Impact factor: 11.685

Review 5.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

Review 6.  Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking.

Authors:  J Stewart
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

7.  Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension.

Authors:  Amie K Lund; Joann Lucero; Lindsay Herbert; Yushi Liu; Jay S Naik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-06-17       Impact factor: 5.464

8.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

Authors:  W Reid; M Sadowska; F Denaro; S Rao; J Foulke; N Hayes; O Jones; D Doodnauth; H Davis; A Sill; P O'Driscoll; D Huso; T Fouts; G Lewis; M Hill; R Kamin-Lewis; C Wei; P Ray; R C Gallo; M Reitz; J Bryant
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

9.  The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART.

Authors:  Jinsong Peng; Michael Vigorito; Xiangqian Liu; Dunjing Zhou; Xiongwen Wu; Sulie L Chang
Journal:  J Neuroimmunol       Date:  2009-11-13       Impact factor: 3.478

Review 10.  HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary.

Authors:  Chris Beyrer
Journal:  Clin Infect Dis       Date:  2007-02-26       Impact factor: 9.079

View more
  13 in total

Review 1.  Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Authors:  Haijun Han; Zhongli Yang; Sulie L Chang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-13       Impact factor: 4.147

2.  Expression profile of nicotinic acetylcholine receptor subunits in the brain of HIV-1 transgenic rats given chronic nicotine treatment.

Authors:  Junran Cao; Tanseli Nesil; Shaolin Wang; Sulie L Chang; Ming D Li
Journal:  J Neurovirol       Date:  2016-04-07       Impact factor: 2.643

3.  Male HIV-1 transgenic rats show reduced cocaine-maintained lever-pressing compared to F344 wildtype rats despite similar baseline locomotion.

Authors:  Y Wendy Huynh; Brady M Thompson; Christopher E Larsen; Shilpa Buch; Ming-Lei Guo; Rick A Bevins; Jennifer E Murray
Journal:  J Exp Anal Behav       Date:  2020-02-20       Impact factor: 2.468

4.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

Review 5.  The HIV-1 transgenic rat model of neuroHIV.

Authors:  Michael Vigorito; Kaitlyn P Connaghan; Sulie L Chang
Journal:  Brain Behav Immun       Date:  2015-02-27       Impact factor: 7.217

6.  Modulation of OPRM1 Alternative Splicing by Morphine and HIV-1 Nef.

Authors:  Martina Donadoni; Wenfei Huang; Shadan S Yarandi; Tricia H Burdo; Sulie L Chang; Ilker K Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2021-08-21       Impact factor: 4.147

Review 7.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

8.  HIV-1 transgenic rats display alterations in immunophenotype and cellular responses associated with aging.

Authors:  Susan J Abbondanzo; Sulie L Chang
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

9.  Effects of Estrogen Receptor Modulators on Morphine Induced Sensitization in Mice Memory.

Authors:  Mahdieh Anoush; Ali Jani; Moosa Sahebgharani; Mohammad Reza Jafari
Journal:  Iran J Psychiatry       Date:  2015-06

10.  Transcriptome sequencing of gene expression in the brain of the HIV-1 transgenic rat.

Authors:  Ming D Li; Junran Cao; Shaolin Wang; Ju Wang; Sraboni Sarkar; Michael Vigorito; Jennie Z Ma; Sulie L Chang
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.